Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Ta...(e the body and administered by infusion ...)

Date:4/6/2009

e the body and administered by infusion (passive immunization). A major stumbling block for immunization is often the inability to generate potent antibodies, especially when the target antigen is complex in nature (GPCR's, ion-channels) or blocked by patents. Pepscan's new and now proven technologies provide an elegant and effective way to arrive at superior immunogens for monoclonals and therapeutic vaccines. Intractable targets are drug targets that would be desirable to address with monoclonal antibodies but are inaccessible with alternative commercially available technologies. This can be due to either it being unavailable as recombinant product (e.g. membrane proteins like GPCRs and ion channels) or the target proteins already being patented. The CLIPS technology makes it possible to derive immunogens from intractable targets that induce antibodies against the native antigen. Ordinary peptides are poor mimics of complex protein structures due to their lack of structure. Pepscan's CLIPSTM technology makes it possible to mimic complex protein domains by presenting one or more amino peptides in a spatially defined conformation. These molecules have proven to be superior in defining discontinuous epitopes. More importantly, CLIPS antigens have now proven to yield antibodies that recognize the protein they are derived from.

Pepscan Therapeutics is a privately owned company based in Lelystad, The Netherlands. Pepscan Therapeutics is wholly owned subsidiary of Pepscan Holding. All fee-for-service activities using Pepscan's technology are handled by Pepscan PRESTO.

http://www.pepscan.com

'/>"/>

SOURCE Pepscan Therapeutics B.V. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related biology technology :

1. Pepscan Achieves First Milestone in Research Collaboration With Genmab
2. Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets
3. VirtualScopics Achieves Operating Cash Flow Breakeven in the Fourth Quarter 2008; Reports Record 2008 Revenue and Gross Profit
4. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
5. BioSyntech Achieves Enrolment Goal for Pivotal Trial of BST-CarGel(R), its Cartilage Repair Device
6. Level 3 Inspection Achieves 100% Compliance in ISO 9001 & AS 9100 Certification
7. Anacor Achieves Milestone from GSK for Boron-Based Systemic Antibacterial Product Candidate
8. Accuray Achieves Milestone of 150th CyberKnife System Installed Worldwide
9. SleepQuest Achieves Coveted Accreditation
10. Bioenergy D-Ribose Achieves Highest Safety Standard
11. Premier Research Achieves Double-Digit Growth in Functional Sourcing for the Third Straight Year